Oncternal Therapeutics, Inc. (ONCT)

Oncternal Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	13.08	6.7	37.14	90.77	116.74	20.05
Short-Term Investments	1.5	27.56	26.58	-	-	-
Cash & Short-Term Investments	14.58	34.26	63.72	90.77	116.74	20.05
Cash Growth	-63.83%	-46.25%	-29.79%	-22.25%	482.20%	-2.88%
Accounts Receivable	0.26	0.49	0.18	0.59	-	-
Other Receivables	0.08	0.14	-	0.36	-	-
Receivables	0.34	0.63	0.18	0.94	-	-
Prepaid Expenses	0.53	1.17	3.39	1.14	1.27	0.74
Total Current Assets	15.45	36.06	67.29	92.85	118	20.79
Property, Plant & Equipment	0.15	0.26	0.09	0.08	0.04	0.19
Other Long-Term Assets	-	0.41	1.27	0.66	0.77	0.77
Total Assets	15.6	36.73	68.65	93.59	118.81	21.74

Liabilities

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Accounts Payable	1.2	1.15	2.92	1.96	1.14	0.87
Accrued Expenses	5.06	3.88	4.68	3.43	3.03	2.71
Current Portion of Leases	0.19	0.17	0.09	0.08	0.04	0.1
Current Unearned Revenue	-	-	-	-	1.63	3.64
Other Current Liabilities	-	-	-	-	0.01	0.02
Total Current Liabilities	6.45	5.2	7.68	5.47	5.86	7.34
Long-Term Leases	-	0.15	-	-	-	0.09
Other Long-Term Liabilities	-	1.33	-	-	-	-
Total Liabilities	6.45	6.68	7.68	5.47	5.86	7.43

Shareholders' Equity

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Common Stock	0	0	0	0.05	0.05	0.02
Additional Paid-In Capital	232.33	227.83	219.26	202.2	195.7	79.87
Retained Earnings	-223.19	-197.78	-158.3	-114.13	-82.8	-65.57
Comprehensive Income & Other	0	0	0.01	-	-	-
Total Common Equity	9.15	30.05	60.97	88.12	112.95	14.31
Shareholders' Equity	9.15	30.05	60.97	88.12	112.95	14.31
Total Liabilities & Equity	15.6	36.73	68.65	93.59	118.81	21.74

Additional Metrics

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Total Debt	0.19	0.32	0.09	0.08	0.04	0.19
Net Cash (Debt)	14.39	33.94	63.64	90.69	116.7	19.86
Net Cash Growth	-64.00%	-46.67%	-29.83%	-22.29%	487.57%	-3.80%
Net Cash Per Share	4.86	11.54	24.20	36.78	114.94	38.46
Filing Date Shares Outstanding	2.96	2.96	2.94	2.47	2.46	0.77
Total Common Shares Outstanding	2.96	2.95	2.87	2.47	2.44	0.77
Working Capital	8.99	30.86	59.61	87.39	112.15	13.45
Book Value Per Share	3.09	10.19	21.22	35.66	46.29	18.60
Tangible Book Value	9.15	30.05	60.97	88.12	112.95	14.31
Tangible Book Value Per Share	3.09	10.19	21.22	35.66	46.29	18.60

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2024

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error